Search

Your search keyword '"Factor X analysis"' showing total 613 results

Search Constraints

Start Over You searched for: Descriptor "Factor X analysis" Remove constraint Descriptor: "Factor X analysis"
613 results on '"Factor X analysis"'

Search Results

1. A Genus-Wide Bioactivity Analysis of Daboia (Viperinae: Viperidae) Viper Venoms Reveals Widespread Variation in Haemotoxic Properties.

2. Vitamin K2 (Menaquinone-7) supplementation does not affect vitamin K-dependent coagulation factors activity in healthy individuals.

Catalog

Books, media, physical & digital resources

3. Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study.

4. A hemophilia A mouse model for the in vivo assessment of emicizumab function.

5. Design and Implementation of an Anti-Factor Xa Heparin Monitoring Protocol.

6. Simple Laboratory Test Utilization Interventions to Reduce Inappropriate Specialty Coagulation Testing.

7. Protease-activated receptors are potential regulators in the development of arterial endofibrosis in high-performance athletes.

8. Procoagulant State in Current and Former Anabolic Androgenic Steroid Abusers.

9. Reduced Requirement for Prothrombin Complex Concentrate for the Restoration of Thrombin Generation in Plasma From Liver Transplant Recipients.

10. Congenital FX Deficiency Rio Tercero: A New Heterozygous Missense Mutation (Cys241Gly) with a Potentiating Effect by a Polymorphism (c. 503-57C>T).

11. Advances in the treatment of bleeding disorders.

12. Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery.

13. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.

14. Ex vivo evaluation of 4 different viscoelastic assays for detecting moderate to severe coagulopathy during liver transplantation.

15. A novel Ala275Val mutation in factor X gene influences its structural compatibility and impairs intracellular trafficking and coagulant activity.

16. [Identification of Target Extracellular Proteases--Activators of Proteins of Haemostasis System Produced by Micromycetes Aspergillus ochraceus and Aspergillus terreus].

17. Effects of storage and thawing conditions on coagulation testing.

18. Consequences for the APTT due to direct action of factor XIa on factor X, resulting in bypassing factors VIII-IX.

19. Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant.

20. Coagulation factor and hemostatic protein content of canine plasma after storage of whole blood at ambient temperature.

21. Monitoring Coumadin-the original oral anticoagulant.

22. Coagulation and fibrinolytic indices during the first trimester of pregnancy in women with polycystic ovary syndrome: a preliminary study.

23. Physiological levels of blood coagulation factors IX and X control coagulation kinetics in an in vitro model of circulating tissue factor.

24. A principal component analysis of coagulation after trauma.

26. Use of the chromogenic factor X assay in patients transitioning from argatroban to warfarin therapy.

27. Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe Factor X deficiency in Iran.

28. Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry.

29. Activation of coagulation in amniotic fluid during normal human pregnancy.

30. Coagulation factors V, VIII, and X, prothrombin time and activated partial thromboplastin time test results in thawed plasma stored at 1-6 ºC for 5 days.

31. Early atherosclerosis exhibits an enhanced procoagulant state.

32. The clinical and laboratory significance of cases of congenital FX deficiency due to defects in the Gla-domain.

33. Warfarin does not interfere with lupus anticoagulant detection by dilute Russell's viper venom time.

34. Comparison of a chromogenic factor X assay with international normalized ratio for monitoring oral anticoagulation therapy.

35. Heparin/heparan sulfate anticoagulant glycosaminoglycans in human plasma of healthy donors: preliminary study on a small group of recruits.

36. Factor XDebrecen: Gly204Arg mutation in factor X causes the synthesis of a non-secretable protein and severe factor X deficiency.

37. Effects of isoflavones on the coagulation and fibrinolytic system of postmenopausal women.

38. Effects of the hormones of the thyroid axis on the vitamin K-dependent plasma factors of blood coagulation (II, VII, IX, and X).

39. A nonstop mutation in the factor (F)X gene of a severely haemorrhagic patient with complete absence of coagulation FX.

40. The discovery of factor X: a personal reminiscence.

41. Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.

42. [Estimation of the correlation between hemostatic parameters and serum lipids in patients with hyperlipidemia type II after simvastatin therapy].

43. Changes of clotting factors (7, 9 and 10) and hepatocyte growth factor in patients with thrombotic microangiopathy after bone marrow transplantation.

44. Poor correlation of supratherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy.

45. Anticoagulant modulation of blood cells and platelet reactivity by garlic oil in experimental diabetes mellitus.

46. A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity.

47. Plasma tissue factor plus activated peripheral mononuclear cells activate factors VII and X in cardiac surgical wounds.

48. Changes in haemostasis during normal pregnancy.

49. Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation.

50. [Expression evaluation of in loco coagulation system in colorectal cancer].